데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
기본 정보
- CAS
80621-81-4- 표준 SMILES
CO[C@H]1/C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C- 분자식
- C43H51N3O11
- 평균 분자량
- 785.89 g/mol
이름 및 식별자
- 우선 이름
- Rifaximin
- 영어명
- Rifaximin
- 분자식
- C43H51N3O11
- 분자량
- 785.89
이름 및 동의어
RIFAMIXINXIFAXANEarthworm Extractl105normixl105svRiimimRIFACOLRifaxinRitacol
데이터베이스 식별자
- CAS
80621-81-4- PubChem CID
- 46783403
물성
물리화학적 성질
- 녹는점
- 200 · 200-2050C (dec)
- 밀도
- 1.36 · 1.36±0.1 g/cm3(Predicted)
- 저장 조건
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- 용해도
- 1 mg/mL · 에탄올: 용해성1mg/mL
- 물리적 상태
- 가루
- 산도 계수 (pKa)
- 2.83 · 2.83±0.70(Predicted)
- 색상
- 다크 오렌지
- Merck
- 14 · 14,8220
- 안정성
- 흡습성
- 주요 응용
- 법의학 및 독성학의약품(소분자)
- InChIKey
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N
- SMILES
- CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c5c(nc6cc(C)ccn56)c4c3C2=O
화학적 성질
Red-Orange Crystalline Powder
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
안전 데이터
- wgk
- 2
- rtecs
- KD1576000
- 독성
- LD50 orally in rats: >2000 mg/kg (Borelli, Bertoli)
- HS 번호
- 2941.90.3000
- 스토리지 클래스
- 11 - Combustible Solids
화학 및 산업
응용 분야
개요Rifaximin is an antibiotic structurally related to rifamycin. It is reported to be efficacious in the treatment of gastrointestinal infections and hepatic encephalopathy, being highly active against Gram-positive and -negative aerobic and anaerobic bacteria. Due to poor systemic absorption, rifaximin is effective in presurgical sterilization of the GI tract.It displays good activity against a wide spectrum of bacteria, including Salmonella spp., S. aureus, and E. coli.
역사Rifaximin was developed by Salix Pharmaceuticals, it is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of non-infectious gastrointestinal diseases like irritable bowel syndrome and hepatic encephalopathy. Rifaximin was originally approved by the US Food and Drug Administration (FDA) in May of 2004 for the management of traveler's diarrhea caused by noninvasive strains of Escherichia coli in patients aged >12 years. On March 24, 2010, rifaximin received an additional labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients aged ≥18 years with advanced liver disease.
용도Rifaximin is a non-absorbable semisynthetic Rifamycin antibiotic.
공급사100 곳
北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
上海瀚鸿科技股份有限公司021-54306202 13764082696 · [email protected]
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…